SCHEMBL5136545

SCHEMBL5136545

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccc(OC)cc1)Cc1ccccc1Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.43
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
ALDH1A1 P00352 5/20 0.37
KDM4E B2RXH2 5/20 0.37
SMN1; SMN2 Q16637 5/20 0.37
LMNA P02545 4/20 0.37
HTT P42858 3/20 0.37
TSHR P16473 3/20 0.37
GAA P10253 3/20 0.37
NPSR1 Q6W5P4 2/20 0.37
TAS2R14 Q9NYV8 1/20 0.37
CNR2 P34972 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
TP53 P04637 4/20 0.37
MAPT P10636 4/20 0.37
HPGD P15428 1/20 0.37
BCHE P06276 3/20 0.36
BLM P54132 1/20 0.36
HSD17B10 Q99714 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5136306 0.94 C5AR1 (0.41) C5AR1MEN1KMT2AALDH1A1KDM4E
SCHEMBL5135238 0.92 C5AR1 (0.45) C5AR1ALDH1A1KDM4ELMNATSHR
SCHEMBL651365 0.92 C5AR1 (0.46) C5AR1ALDH1A1KDM4ESMN1; SMN2LMNA
SCHEMBL4766354 0.91 C5AR1 (0.41) C5AR1ALDH1A1KDM4ESMN1; SMN2LMNA
SCHEMBL5136679 0.91 C5AR1 (0.44) C5AR1ALDH1A1KDM4ESMN1; SMN2LMNA
SCHEMBL5137368 0.91 TP53 (0.46) C5AR1ALDH1A1KDM4ESMN1; SMN2LMNA
SCHEMBL5072205 0.91 C5AR1 (0.46) C5AR1MEN1KMT2AALDH1A1KDM4E
SCHEMBL5134673 0.90 C5AR1 (0.43) C5AR1ALDH1A1KDM4ESMN1; SMN2LMNA
SCHEMBL5136291 0.90 C5AR1 (0.45) C5AR1ALDH1A1KDM4ESMN1; SMN2LMNA
SCHEMBL5135905 0.89 C5AR1 (0.45) C5AR1ALDH1A1KDM4ESMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed